Lilly Drug Reduces Blindness in Diabetic Patients
14th Nov 2006, 13:38 GMT
Eli Lilly has said results from a three-year phase III clinical trial suggested its experimental drug Arxxant reduced the risk of vision loss by 40% in patients with diabetic retinopathy.
Lilly Drug Reduces Blindness in Diabetic Patients related news:
- Lilly drug reduces blindness in diabetic patients — Pharmaceutical Business Review Latest News
- Lilly: Arxxant cuts sight loss in diabetes — United Press International - Health Business
- Study Favors TAXUS Stent Over Cypher Stent and Bare-Metal Stents in Diabetic Patients — Nephrology/ Dialysis News from StratCenter.com
- Enzyme May Hold Key To New Treatment Of Diabetic Kidney Disease — ScienceDaily Headlines: Health & Medicine
- November 8, 2006: In the News — Medscape Headlines
- FDA Proposes 'Abnormal Behavior' Warning for Tamiflu — KLTV - Local and National News
- Goat Riders of the Apocalypse :: Goat Riders: Hot Stove: Cubs contact Lilly, interested in Soriano — Sports Blogs :: Chicago Cubs Daily Entries
- Late angioplasty after heart attack no better than drug therapy — EurekAlert! - Breaking News
- Doctors Rarely Discuss Drug Costs With Patients — KeepMedia: KeepMedia Home
- FDA Orders Caution Over the use of Tamiflu — NPR Topics: Nation
Latest news from RedOrbit News - Health:
- Pet Shop Boys Fans Know Better _ Why Bother Sharing?
- Corcept Tests Psych. Major Depression Rx
- On Its 30th Anniversary, Smokeout Provides Even More Help Quitting Smoking
- Health Plans and Disease Management Companies Are Seeking To Reduce the Use of the ER for Non-Urgent Care - Urgent Emergency Room Usage October 18, 2006 Audio Conference on CD-ROM
- Invitation Conference Call Analyst Meeting
- As Benefit Costs Rise, Employee Retirement Savings Decline
- Aetna to Help Members Quit Tobacco With New Tobacco Cessation Program
- Lilly: Arxxant Cuts Sight Loss in Diabetes
- SW Doctors PA Launch Affordable Primary Care (APC) Services
- Health Savings Technology Appoints New Management Team to Spearhead Growth in Customer-Directed Healthcare Industry